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Abstract 
The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncol‑
ogy and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel 
synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic 
signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical 
efficacy and minimized adverse effects compared with traditional treatments, the challenging drug‑resistant issue has 
also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by present‑
ing a systematic framework regarding the drug resistance mechanisms and alternative approaches to re‑sensitize 
cancer cells/tissues therapeutically.
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Background
Anti-cancer drugs represent an efficacious weapon in 
the human defensive war against neoplastic diseases. 
As an ever-evolving force in fighting malignancies and 
improving patients’ quality of life, drug-therapeutic 
approaches have progressed through several milestones 
including cytotoxic compounds, hormonal treatments, 
targeted therapies, and combinational regimens. Anti-
cancer drugs in the early period, such as 5-fluorouracil 
and methotrexate, were generally cytotoxic medicines 
without specific molecular targets. They usually killed 
rapidly dividing (cancer) cells by inhibiting DNA synthe-
sis or related enzymes. Unfortunately, some normal cells, 
for example bone marrow and hair cells in the body, also 
divide very rapidly and were coincidently affected, result-
ing in severe adverse effects [1, 2]. Four decades ago, the 
rise of hormonal therapy, such as tamoxifen for breast 
cancer, has remarkably enhanced tissue selectivity and 
thereby diminished adverse systematic events [3]. How-
ever, the utility of hormonal therapy is limited to a few 
types of tumors with high sexual hormone activity as the 
driving force for growth.
During the last two decades, dramatic breakthroughs 
in cellular and molecular biology have resulted in the 
delineation of particular signaling pathways that control 
proliferation, cell death/differentiation, angiogenesis, and 
metabolism. As a result, this exciting scientific progress 
has been deeply inspiring innovative drug research and 
development, to undergo a fundamental transforma-
tion toward targeted therapy. To date, two categories of 
targeted therapeutic agents with unique properties in 
oncology, namely synthetic chemical compounds and 
recombinant monoclonal antibodies, are known to have 
achieved clinical successes [4, 5]. Most of the chemi-
cal compounds were designed to function as oncogenic 
kinase inhibitors that have good bioavailability, good tol-
erability, and few adverse effects. In contrast, therapeu-
tic antibodies have prolonged half-lives in plasma, highly 
molecule-targeting specificity, and minimal off-target 
toxicity (if any).
Targeted therapy in the clinic is capable of delivering 
clear benefits to patients as evidenced by improvement in 
overall survival (OS), progression-free survival (PFS), and 
response rate (RR), among other end points. Effective 
anti-cancer treatments have so far been able to eliminate 
macroscopic tumors both at primary sites and at com-
mon distal sites. Nevertheless, even if they showed an 
impressive response to treatment initially, the majority of 
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cancer patients relapsed because small cohorts of tumor 
cells can survive in cryptic anatomic loci and exhibit up 
to 90% resistance to one or more therapeutic agents for 
months or year(s). As such, drug resistance has been a 
major hurdle for classic anti-cancer medicines [1], and it 
still is a great challenge facing the emerged array of tar-
geted therapies [2, 6]. Herein, we provide a comprehen-
sive overview regarding targeted therapy resistance and 
alternative strategies in oncology (Table 1).
Breakpoint cluster region‑Abelson (BCR‑ABL) 
inhibitor
Imatinib (Gleevec, Novartis, Basel, Switzerland) revolu-
tionized therapeutic strategies for chronic myeloid leu-
kemia (CML) through targeting the BCR-ABL fusion 
protein, which drives constitutive tyrosine kinase activ-
ity and in turn the malignant behaviors of leukemic cells 
[7]. Impressively, imatinib has been able to extend 5-year 
OS rate of CML patients beyond traditional treatments, 
thereby re-defining CML as a manageable disease [25]. 
Additionally, imatinib is also a potent antagonist of c-kit 
receptor tyrosine kinase (c-KIT) and platelet-derived 
growth factor receptor A (PDGFRA) kinase, both of 
which cause gastrointestinal stromal tumors (GIST) [26]. 
In the pharmaceutical industry, the success of imatinib 
evoked a huge wave of efforts to develop various dis-
ease-associated kinase inhibitors. However, as an era of 
targeted therapy comes following the light of the first 
BCR-ABL inhibitor, resistance to imatinib is emerging as 
a major challenge in CML management.
Imatinib resistance results from complicated mecha-
nisms including up-regulated multidrug resistance 
(MDR) proteins. However, mutations (such as T315I) in 
the BCR-ABL gene were revealed to be the most com-
mon mechanism behind imatinib resistance, and they 
associate with an advanced disease state (accelerated 
or blast-phase CML). Imatinib works as an adenosine 
triphosphate (ATP) mimetic compound, and it only binds 
Table 1 Anti‑cancer drugs for targeted therapy
BCR-ABL breakpoint cluster region-Abelson, CML chronic myeloid leukemia, KIT kit receptor tyrosine kinase, GIST gastrointestinal stromal tumor, PDGFRA platelet-
derived growth factor receptor A, EGFR epidermal growth factor receptor, NSCLC non–small cell lung cancer, ALK anaplastic lymphoma kinase, HER2 human EGFR2, 
VEGF(R) vascular endothelial cell growth factor (receptor), HIF1 hypoxia-inducible factor 1, MDSC myeloid-derived suppressor cell, CSC cancer stem cell, BRAF raf 
murine sarcoma viral oncogene homolog B, MAPK mitogen-activated protein kinase, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1
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to the inactive conformation of the enzyme. Mutations 
of BCR-ABL that fix the kinase domain in its active con-
figuration result in diminished binding to the compound 
and, therefore, a loss of inhibitory potency. To address 
imatinib resistance issue in CML, new-generation inhibi-
tors, such as dasatinib, nilotinib, and ponatinib, were 
developed to suppress the enzyme with a capability of 
potently binding its active conformation [7]. Likewise, in 
the case of GIST, imatinib resistance mainly results from 
mutations of the c-KIT and PDGFRA genes. Primary 
resistance in GIST occurs in 6  months of drug treat-
ment, and it is due to mutations in catalytic domain of 
c-KIT (exon 9) or PDGFRA (D842V). Moreover, second-
ary resistance to imatinib appears approximately 2 years 
after the treatment, and it is associated with alternative 
c-KIT mutations such as V654A and N822K plus exon 11 
mutations. In response to these challenges, sunitinib and 
regorafenib have been developed to serve as second- and 
third-generation inhibitors, respectively, for GIST treat-
ment [2, 7, 8].
Inhibitors of epidermal growth factor receptor 
(EGFR) and anaplastic lymphoma kinase (ALK)
EGFR represents a member of the cell surface receptor 
tyrosine kinase (RTK) molecular family, and it is activated 
upon ligand binding as well as receptor dimerization. The 
activation of EGFR and its down-stream pathways, such 
as extracellular receptor kinase (ERK) and protein kinase 
B (AKT), substantially contributes to cell proliferation, 
survival, migration, and angiogenesis. Up-regulation of 
EGFR signaling activity occurs in many types of cancers 
and is thus an attractive target for contemporary drug 
development [27]. EGFR inhibitors that are currently 
available include gefitinib, erlotinib, monoclonal anti-
body cetuximab, and others [9]. Being less toxic, gefitinib 
and erlotinib have been reported to be superior to con-
ventional cytotoxic chemotherapy in terms of RR and 
PFS time in lung adenocarcinoma patients with EGFR 
mutations such as L858R (EGFR addiction). In addi-
tion, cetuximab in combination with radiation in head 
and neck cancer has delivered more impressive benefits, 
increasing the 2-year OS rate of the patients [13]. Addi-
tionally, cetuximab was approved for treating metastatic 
and chemotherapy-resistant colorectal cancer due to its 
clinical efficacy with improved PFS and RR [10, 13].
Not all EGFR-expressing cancers respond to targeted 
inhibitor treatment. Moreover, those patients that ben-
efit from EGFR inhibitors beyond conventional chemo-
therapy initially become resistant to the targeted therapy 
inevitably after approximately 1 year. The most common 
mechanism of primary and acquired resistance to EGFR 
inhibitor in lung cancer is the T790  M “gatekeeper” 
mutation, for which a currently available solution is 
combining cetuximab with afatinid. However, an EGFR 
mutation S492R in colorectal cancer leads to resistance 
to cetuximab, which can be overcome by the newer EGFR 
antibody panitumumab. Meanwhile, it is anticipated 
that EGFR inhibitors of second- or third-generation will 
be coming out to overcome target-resistant cancers. Of 
note, most malignancies with high EGFR expression can 
be multi-signaling cascade-driven disorders under cer-
tain circumstances. Depending on the cellular/molecular 
contexts, many other compensatory pathways, such as 
Ras/phosphatidylinositol-3-kinases (PI3K) mutations and 
MET/human epidermal growth factor receptor 2 (HER2) 
high activity, have also been found to contribute to EGFR 
inhibitor resistance [11, 12]. Accordingly, a combination 
of EGFR with PI3K or MET pathway inhibitors appears 
necessary in this case.
Interestingly, a chromosomal translocation-induced 
ALK activation has been identified in 3–5% of non–
small cell lung cancer (NSCLC) patients, and is clinically 
linked to a more aggressive phenotype. This subset of 
lung cancer is addicted to high ALK activity for malig-
nant growth, and in general it is dramatically sensitive 
to ALK-targeted agents such as crizotinib. Although the 
ALK inhibitor was able to significantly improve the clini-
cal outcome of NSCLC patients with a RR of 60% and a 
PFS of 10 months, the emergence of resistance to crizo-
tinib has been noticed as a challenge [14, 15]. Similar to 
the scenarios in the above therapeutic targets, the ALK 
gene mutations such as C1156Y and L1196M have been 
reported as the molecular mode of crizotinib resistance 
[14]. Moreover, alternative signaling activation, including 
EGFR and c-KIT, was proposed to be a minor mechanism 
[2]. To address this issue, ALK inhibitors of new genera-
tion, such as LDK378 and AP26131, are currently in clini-
cal trials and have shown encouraging efficacy [15].
Human EGFR2 (HER2) antibody
Breast cancer consists of a heterogeneous mass of path-
ologic conditions which, for therapeutic guidance pur-
poses, are classified as hormone receptor–positive, 
human EGFR2–positive (HER2+), or triple-negative 
groups. Strategies targeting the estrogen receptor (ER) 
and HER2 to treat breast cancer have come up with some 
of the most successful drugs in oncology. HER2 is overex-
pressed in 25–30% of breast cancer patients, predicting a 
poor clinical outcome in the absence of targeted therapy 
[27, 28]. Trastuzumab (Herceptin) is a humanized mono-
clonal antibody targeting the extracellular domain of the 
HER2 protein, and trastuzumab plus chemotherapy has 
been accepted as the standard first-line treatment for 
HER2-positive metastatic breast cancer (MBC). Appli-
cation of trastuzumab was revealed to confer extra-
clinical benefits to HER2-positive breast patients with 
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significantly longer PFS, higher RR, and reduced relapse 
compared with conventional therapy [29]. Even if the 
cancer progresses on trastuzumab, the anti-cancer drug 
is still recommended for continuation due to its proven 
clinical efficacy on slowing tumor growth [29, 30].
The majority of HER2-positive breast cancer patients 
would not respond to trastuzumab without simultaneous 
cytotoxic therapy. It has been proposed that trastuzumab 
exerts clinical efficacy mainly through sensitizing tumor 
cells to DNA damage by cytotoxic chemotherapy [2, 30]. 
Notably, a truncated 95–100  kDa receptor (p95HER2), 
expressed in a minor portion of HER2-positive breast 
cancer patients, leads to an aggressive trastuzumab-
resistant phenotype due to its lack of the extracellular 
domain of HER2 targeted by trastuzumab [16]. Moreover, 
enhanced HER2 dimerization resulting from PI3 K muta-
tions and/or loss of phosphatase and tensin homolog 
(PTEN) was identified to play an important role in sec-
ondary resistance to trastuzumab [2, 27]. To circumvent 
these problems, pertuzumab, a newer HER2 antibody, 
has been developed to disturb HER2/HER3 dimerization, 
thereby augmenting trastuzumab activity [17]. In addi-
tion, trastuzumab emtansine, derived from covalently 
conjugating a cytotoxic compound with the antibody, 
retains therapeutic activity in patients resistant to tras-
tuzumab. Moreover, lapatinib, a reversible inhibitor of 
EGFR and HER2, has been approved to treat HER2-posi-
tive breast cancer upon trastuzumab failure [28].
Vascular endothelial growth factor (VEGF) 
antagonists
The VEGF to its receptor (VEGFR) signaling plays a piv-
otal role in new blood vessel formation termed angio-
genesis, and this activity is significantly up-regulated in 
solid tumor tissues upon growth beyond 1  mm in size. 
In corollary, approaches targeting tumor angiogen-
esis represent an exciting option in anti-cancer therapy 
through modulating the microenvironment [31]. Beva-
cizumab (Avastin), a humanized VEGF-A neutralizing 
antibody, represents the first-generation agent of anti-
tumor angiogenesis and has been approved to treat sev-
eral types of malignancies in combination with cytotoxic 
chemotherapy, including colon, lung, and renal cancers 
[32]. Later on, inspired by this idea, more VEGF/VEGFR 
antagonists, including decoy receptors and small chemi-
cal inhibitors, were developed and have also achieved 
clinical success [2]. Interestingly, the VEGFR inhibitors 
sunitinib and vandetanib coincidentally inhibit c-KIT 
and rearranged during transfection (RET) genes, thereby 
having additional benefits for treating GIST and medul-
lary thyroid carcinoma, respectively [18]. After showing 
dramatic anti-tumor efficacy in animal models, various 
angiogenesis inhibitors have so far conferred moderate 
improvements in PFS, RR, and OS in patients with cer-
tain cancer types in the clinic [18, 19].
Even though mutations of receptor or kinase domain 
genes have been identified as the major reason of resist-
ance to other targeted therapies such as ACR-ABL and 
EGFR inhibitors, this is not the case in VEGF-targeted 
drug resistance. The mechanisms behind resistance to 
VEGF antagonists are complex and have not been com-
pletely understood yet. Notably, there are a variety of 
alternative signaling molecules, such as placental growth 
factor (PIGF), fibroblast growth factor (FGF), and angi-
opoietin, which can bypass VEGF/VEGFR inhibition and 
restore tumor angiogenesis. In this regard, adding inhibi-
tors against these alternative angiogenesis targets to 
therapeutic programs has been proposed to be helpful for 
overcoming anti-VEGF resistance [2, 19]. Furthermore, 
continued inhibition of angiogenesis creates a hypoxic 
environment and in turn induces secondary pathologic 
alterations in tumor tissues, including increased hypoxia 
inducible factor 1 α (HIF1α), myeloid-derived suppres-
sor cells (MDSCs), and cancer stem cells (CSCs). As a 
transcription factor, HIF1α up-regulates a wide array of 
genes associated with cell survival and anaerobic metab-
olism [20]. Meanwhile, cancer and stromal cells secrete 
granulocyte colony-stimulating factor (GCSF) and thus 
activate MDSCs which also contribute to drug resistance 
via suppressing immune activity against cancer in the 
tumor microenvironment. Recently, CSCs have been rec-
ognized as a particular subpopulation of cancer cells that 
are responsible for metastasis and therapeutic resistance 
[33]. In this sense, to solve anti-VEGF drug resistance 
problems in the long-term, the hypoxia-induced second-
ary pathologic changes need to be reversed by combining 
with certain therapeutic means accordingly.
Raf murine sarcoma viral oncogene homolog B 
(BRAF) inhibitor
The serine/threonine kinase BRAF serves as a crucial 
mediator in rat sarcoma (RAS) mitogen-activated pro-
tein kinase (MAPK) signaling cascade which represents 
a defined pathway driving cell growth and becomes an 
oncogene upon mutation. To date, BRAF mutations have 
been identified in many types of tumors, and are highly 
frequent in melanoma, colorectal cancer, and papil-
lary thyroid cancer. Over 50% of melanomas bear BRAF 
mutations at the advanced stage, of which approximately 
80% appear as the substitution of glutamic acid (E) for 
valine (V) in codon 600, known as the V600E mutation, 
and approximately 16% as the V600K mutation. To cir-
cumvent these molecular targets, vemurafenib, a highly 
selective inhibitor of BRAF V600E mutation, was devel-
oped and have shown clear clinical benefits including sig-
nificantly better response and higher OS rates compared 
Page 5 of 6Chen and Zhang  Chin J Cancer  (2015) 34:43 
with commonly utilized standard chemotherapy agents 
[22]. Recently, another BRAF mutation inhibitor, dab-
rafenib, has been approved by the United States Food and 
Drug Administration (FDA) based on its clinical benefits 
of better PFS and RR. Excitingly, these two compounds 
represent the first drugs showing clinical benefits in 
patients with melanoma metastasis to the brain [23].
In spite of an impressive RR of 50% with vemurafenib 
and dabrafenib initially, acquired resistance to these 
drugs occurs after approximately 6 months. Distinct from 
the mechanisms in other tumors, secondary mutations 
of the target gene in melanomas have not been found. 
Instead, BRAF amplification and new BRAF V600E splice 
isoforms appear to account for the drug resistance [24]. 
Another possibility is BRAF-independent MAPK activa-
tion due to Ras bypass signaling or MEK mutations [2]. In 
this light, combining the MEK inhibitor trametinib with 
BRAF inhibitors in melanoma treatments has resulted 
better clinical outcomes than either therapy alone [23, 
24]. Interestingly, the blocking antibodies (ipilimumab 
and nivolumab) of co-suppressing molecules cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death protein 1 (PD-1)/programmed 
death-ligand 1 (PD-L1) in immune cells have emerged 
to be quite promising in treating immunity-associated 
malignancies such as melanoma. To date, these immune 
cell–modulating antibodies added to therapeutic pro-
grams for melanomas have shown greater clinical effi-
cacy and improved toxic profiles [34]. Impressively, the 
therapeutic response duration with nivolumab has been 
extended beyond 2 years [23].
Conclusion and perspective
As a contemporary hallmark of medical oncology and 
innovation in pharmaceutical industry, targeted therapy 
provides physicians and patients with more options to 
improve clinical outcomes. Although imatinib has trans-
formed CML into a manageable medical condition like 
other non-malignant diseases in several ways [25], the 
clinical benefits from most targeted therapies are lim-
ited, extending PFS or OS of cancer patients by only a 
few months, and resistance is eventually faced, followed 
by tumor aggression. There has been a consensus that, to 
improve the results of targeted therapy, challenging drug 
resistance problems needs to be solved through better 
understanding the mechanisms.
Unlike cytotoxic medicines in which modes of resist-
ance are mainly attributed to dysregulated pharma-
cokinetic processes such as increased drug efflux out of 
responding cells mediated via MDR gene-encoded pro-
tein transporters [35], resistance to targeted therapy in 
oncology usually results from target gene mutation(s) 
and redundant activation of other pro-survival signaling 
pathways. In this sense, combination therapy with forth-
coming next-generation agents targeting resistance-asso-
ciated mutations and pathways appears to be a helpful 
strategy to circumvent the challenge. To do so smartly, it 
is necessary to note that selective biomarkers have come 
up with predictive information concerning the thera-
peutic sensitivity [36, 37] and enhanced the likelihood of 
right drug(s) for each individual patient which is regarded 
as personalized medicine. Furthermore, cancer genome 
monitoring and microRNA profiling [38] are being 
actively translated from bench to bedside in oncology, to 
hopefully help therapeutic selection and adjustment.
We should not ignore certain emerging scientific con-
cepts with translational potential, such as CSCs which 
are speculated as the “root” for malignant recurrence 
and metastasis, being often linked to drug resistance. 
A variety of CSC inhibitors, either novel agents or old 
compounds from therapeutic repositioning, are increas-
ingly available and able to improve clinical outcomes 
[21, 33]. In addition, the renaissance of cancer immunol-
ogy in recent years has dramatically inspired oncology 
with several immune co-regulator targeting antibodies 
that deliver impressive clinical benefits [34], including 
extending the therapeutic response time to over 2 years 
[23]. Thus, it is conceivable that the body’s defense sys-
tem holds deep resources to be explored to improve 
clinical outcomes such as overcoming drug resistance in 
oncology.
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